Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 54c
Tweet
Share
E-mailGet Alerts ACRV Hot Sheet
Join SI Premium – FREE
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q2 EPS of ($0.55), $0.54 better than the analyst estimate of ($1.09).
For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- ArcBest Corp (ARCB) Reiterated at Market Outperform by Citizens Post 75th ACT Seminar
- Zoom (ZM) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
